期刊
LANCET NEUROLOGY
卷 10, 期 7, 页码 649-656出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(11)70121-1
关键词
-
资金
- FISM
- Italian Ministry of Health (Ricerca Finalizzata)
- Italian Ministry of University and Scientific Research (MIUR)
- Progetto Limonte
- Fondazione Carige
- Roche
- Allergan
- Biogen Idec
- Genentech
- Merck Serono
- Sanofi-Aventis
- Biogen-Dompe
- Novartis
- Bayer-Schering
- Bayer
- Teva
- Celgene
- Lansdowne DIME
- Medscape
- Genzyme
The rationale for use of adult stem cells as a treatment for neurological diseases such as multiple sclerosis arose from the hope that they had the capacity to foster repair of the CNS through tissue integration and differentiation into neural cells. Evidence from preclinical studies suggested that mesenchymal stem cells (MSCs), a subset of adult progenitor cells, are an effective therapy in preclinical animal models of neurological diseases such as experimental autoimmune encephalomyelitis, a model for multiple sclerosis, and stroke. In experimental autoimmune encephalomyelitis, intravenous injection of MSCs ameliorates clinical course and decreases demyelination, immune infiltrates, and axonal loss. Surprisingly, these effects do not require full CNS engraftment by MSCs, but rely on the capacity of MSCs to inhibit pathogenic immune responses and release neuroprotective and pro-oligodendrogenic molecules favouring tissue repair. These results led to the conclusion that therapeutic use of MSCs should initially focus on individuals with multiple sclerosis and persistent inflammation. Small clinical studies in different neurological diseases have suggested that MSCs are safe, paving the road for larger phase 2 studies addressing the effect of MSCs on clinical outcomes and markers of disease activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据